Emergent BioSolutions Inc. shareholders can proceed in part with a lawsuit over sharp stock declines following news of contaminated Covid-19 vaccine batches at the company’s production facility and a canceled government contract, a federal court ruled.
The investors plausibly alleged numerous intentional, material misrepresentations and omissions by two executives and the company about its manufacturing operations, Judge Deborah L. Boardman said Sept. 1 for the US District Court for the District of Maryland.
Mold, staffing, and other problems at the company’s Bayview facility in Baltimore in 2020 and 2021 led to the destruction or withholding of millions of doses of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.